Etzer Darout
Stock Analyst at BMO Capital
(2.07)
# 2,908
Out of 4,941 analysts
111
Total ratings
37.35%
Success rate
-4.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Outperform | $57 → $45 | $32.20 | +39.75% | 4 | Aug 7, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $26 → $15 | $6.53 | +129.71% | 5 | May 13, 2025 | |
| IVA Inventiva | Maintains: Buy | $12 → $9 | $3.67 | +145.23% | 3 | Apr 4, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $82 → $20 | $6.80 | +194.33% | 4 | Mar 12, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $62 → $72 | $54.53 | +32.04% | 2 | Mar 11, 2025 | |
| BNTX BioNTech SE | Maintains: Outperform | $130 → $143 | $111.00 | +28.83% | 4 | Mar 11, 2025 | |
| MRUS Merus | Maintains: Outperform | $91 → $96 | $63.76 | +50.56% | 6 | Feb 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $1.68 | +78.57% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.30 | +53.85% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $37.95 | +5.40% | 3 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $21.43 | +133.32% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $10.02 | +249.30% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $55 | $39.87 | +37.95% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $2.85 | +2,110.53% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.25 | +2,060.00% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $76.67 | +74.78% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $7.75 | +338.71% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $21.87 | +119.48% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $119.31 | +0.58% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $8.51 | +193.77% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.47 | +240.14% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $2.24 | +792.86% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $0.94 | +540.82% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $1.86 | +93.01% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $75.34 | +8.84% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.87 | +290.14% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $429.93 | -60.46% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $48.03 | +12.43% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $64.72 | -41.29% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.64 | +3,070.73% | 1 | Mar 28, 2018 |
Scholar Rock Holding
Aug 7, 2025
Maintains: Outperform
Price Target: $57 → $45
Current: $32.20
Upside: +39.75%
Terns Pharmaceuticals
May 13, 2025
Maintains: Outperform
Price Target: $26 → $15
Current: $6.53
Upside: +129.71%
Inventiva
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.67
Upside: +145.23%
Arvinas
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $6.80
Upside: +194.33%
Protagonist Therapeutics
Mar 11, 2025
Reiterates: Outperform
Price Target: $62 → $72
Current: $54.53
Upside: +32.04%
BioNTech SE
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $111.00
Upside: +28.83%
Merus
Feb 28, 2025
Maintains: Outperform
Price Target: $91 → $96
Current: $63.76
Upside: +50.56%
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $1.68
Upside: +78.57%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.30
Upside: +53.85%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $37.95
Upside: +5.40%
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $21.43
Upside: +133.32%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $10.02
Upside: +249.30%
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $39.87
Upside: +37.95%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $2.85
Upside: +2,110.53%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.25
Upside: +2,060.00%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $76.67
Upside: +74.78%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $7.75
Upside: +338.71%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $21.87
Upside: +119.48%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $119.31
Upside: +0.58%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $8.51
Upside: +193.77%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.47
Upside: +240.14%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.24
Upside: +792.86%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $0.94
Upside: +540.82%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $1.86
Upside: +93.01%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $75.34
Upside: +8.84%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.87
Upside: +290.14%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $429.93
Upside: -60.46%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $48.03
Upside: +12.43%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $64.72
Upside: -41.29%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.64
Upside: +3,070.73%